摘要
循证医学强调，任何医疗决策的制定都应遵循和应用最新、最佳研究证据的理念，使现代医学由经验走向科学，由实验走向临床，为临床诊治提供强有力的医学方法论和决策手段。循证医学认为，
出处
《中华妇产科杂志》
CAS
CSCD
北大核心
2012年第8期582-586,共5页
Chinese Journal of Obstetrics and Gynecology
参考文献24
-
1Marchetti C, Pisano C, Facchini G, et al. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Hev Anticancer Ther ,20 I 0, 10 :47 -60.
-
2Aabo K, Adams M, Adnill P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Triuiists ' Group. Br J Cancer, 1998,78:1479-1487.
-
3Chemotberapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group. Cochrane Database Syst Hev , 2000 ( 2 ) : C])001418.
-
4Hiigberg T, Climelius B, Nygren P, et al. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol,2001 ,40: 340-360.
-
5Parmar M K, Ledermann J A, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON41 AGO-OVAH-2.2 trial. Lancet,2003 ,361 :2099-2106.
-
6McCuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage lV ovarian cancer. N Engl J Me", 1996, 334:1-6.
-
7Pier-art MJ, Bertelsen K, James K, et al. Randomized intergroup trial of ?isplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J Natl Cancer Inst,2000,92 :699-708.
-
8du Bois A, LUck HJ, Meier W, d al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paelitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst,2003,95:1320-1329.
-
9Bookman MA, Greer BE, Ozols HF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and pa.-litaxel ((;OGI58) and an update on GOG0l82-ICON5. Int J Cynecol Cancer,20m, 13 Suppl2: 149-155.
-
10Pignata S, Sc-amhin G, Ferrand ina G, et al. Carboplatin plus paclitaxel versus ?arboplatin plus pegylated liposomal doxoruhicin as first-line treatment lor patients with ovarian cancer: the M1T0-2 randomized phase III trial. J Clin Oneol,2011 ,29 :3628-3635.
同被引文献10
-
1Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxombicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse [ J ]. J Ciin Oncol,20!0,28 (20) :3323 - 3329.
-
2Marchetti C,Pisano C, Facchini G, et al. First-line treatment of ad- vanced ovarian cancer: current research and perspectives[ J]. Expert Rev Anticancer Ther,2010,10( 1 ) :47 -60.
-
3Laviolette LA, Garson K, Macdonald EA, et al. 17beta-estradiol ac- celerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer [ J]. Endocrinology, 2010, 151 ( 3 ) : 929 - 938.
-
4Langdon SP, Smyth JF. Hormone therapy for epithelial ovarian cancer [J]. Curr Opin Oncol,2008,20(5) :548 -553.
-
5Li YF, Hu W, Fu SQ. Aromatase inhibitors in ovarian cancer:is there a role? [J]. Int J Gynecol Cancer,2008,18(4) :600 -614.
-
6Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study [ J ]. Oncology, 2004,66 ( 2 ) : 112 - 117.
-
7Smyth JF, Gourley C, Walker G, et al. Antiestregen therapy is active in selected ovarian cancer cases:the use of letrozole in estrogen re- ceptor-positive patients[ J]. Clin cancer Res,2007,13 ( 12 ) : 3617 - 3622.
-
8Ramirez PT,Schmeler KM,Milam MR,et al. Efl3cacy of letrozole in the treatment of recurrent platinum-and taxane-resistant high-grade cancer of the ovaryor peritoneum [ J ]. Gynecol Oncol, 2008, 110 (1) :56 -59.
-
9袁光文,吴令英,姚洪文,侯进琳,李晓光,刘丽影.复发卵巢上皮性癌的治疗与预后分析[J].中华肿瘤杂志,2009,31(9):710-714. 被引量：4
-
10马爱清,张秦,刘琦.芳香化酶抑制剂在卵巢癌治疗中的作用[J].医学研究生学报,2012,25(11):1217-1220. 被引量：7
-
1史瑞芬,吴红玲.内科护理教学中整体观的运用[J].华南国防医学杂志,1999,13(1):41-42.
-
2王洪奇.基因诊断技术及其伦理问题初探[J].中国医学伦理学,2002,15(6):39-42.
-
3张颖兰,余爱敏,茹玉.卵巢上皮性癌术后静脉化疗期的血管保护[J].全科护理,2012,10(21):1978-1979.
-
4李丽,薄其美,卢克新.紫杉醇联合顺铂治疗卵巢上皮性癌疗效分析[J].中国基层医药,2012,19(13):1978-1979.
-
5刘红秀.卵巢上皮性癌的临床综合治疗与疗效分析[J].内蒙古中医药,2009(4):49-50.
-
6毛咏红.手术结合化疗治疗卵巢上皮性癌的临床效果分析[J].中外医疗,2009,28(10):55-55. 被引量：1
-
7梁致怡,张虹.卵巢上皮性癌和血小板计数增高相关性分析[J].中国肿瘤临床,2008,35(13):729-732. 被引量：4
-
8昌晓红,熊英,崔恒.卵巢上皮性癌标志物的研究进展[J].中华妇产科杂志,2008,43(1):66-68. 被引量：14
-
9李佳.紫杉醇在卵巢癌治疗中的护理[J].中国社区医师（医学专业）,2009,11(24):218-218.
-
10赵青平,李卫东,等.试论在新形式下做好基层医院的血库管理工作[J].中华综合医学,2002,3(10):939-940. 被引量：1
